⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Frontiers in PharmacologyOpen Access

Bufei Huoxue capsule attenuates COPD-related inflammation and regulates intestinal microflora, metabolites

Yuanyuan Li Jiali Chen Yue Xing Jian Wang Qiuling Liang Jiamin Zeng Siyi Wang Qiong Yang Jianing Lu Jieying Hu Wenju Lu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Bufei Huoxue capsule (BFHX) is widely used for the clinical treatment of chronic obstructive pulmonary disease (COPD) in China.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcafb6db643587676cd2 https://doi.org/10.3389/fphar.2024.1270661

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prospects for the Protective Mechanisms and Compounds of Bufei Huoxue Capsule against COVID-19 Convalescence: Evaluation of Integrating UHPLC-HRMS Analysis and Network Pharmacology Strategy2024
2Bufei huoxue capsule alleviates bleomycin-induced pulmonary fibrosis in mice via TGF-β1/Smad2/3 signalingpreclinical · 2023 · 40 citations
3New insight into the molecular mechanism of TCM Bufei Huoxue formula for chronic obstructive pulmonary disease based on network pharmacology and experimental verification2024
4Integrated approach of network pharmacology, molecular docking, and clinical observations in evaluating the efficacy and safety of Bufei Huoxue capsules for pulmonary hypertension associated with chronic obstructive pulmonary disease2024 · 2 citations
5Integrated Metabolomic and Gut Microbiome Analyses Reveal the Therapeutic Effects of Xuanfei Heji in Rats With Chronic Obstructive Pulmonary DiseaseOriginal Research · 2026